Nexstim Plc: Managers’ Transactions

[ASFN Admin]

Company announcement, Helsinki, 29 March 2021 at 12 pm (EEST) Nexstim Plc: Managers’ Transactions Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to the notification requirementName: Forss MartinPosition: Member of the Board/Deputy memberIssuer: Nexstim OyjLEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATIONReference number: 743700S7ZI0LNMHZ6Y27_20210326151605_2____________________________________________ Transaction date: 2021-03-24Venue: FIRST NORTH FINLAND (FNFI)Instrument type: SHAREISIN: FI4000480470Nature of the transaction: SUBSCRIPTION Transaction details(1): Volume: 133,533 Unit price: .03 EUR Aggregated transactions(1): Volume: 133,533 Volume weighted average price: .03 EUR____________________________________________ Transaction date: 2020-04-06Venue: FIRST NORTH FINLAND (FNFI)Instrument type: SHAREISIN: FI4000480470Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS)(X) Linked to stock option programme Transaction details(1): Volume: 17,067 Unit price: .26 EUR Aggregated transactions(1): Volume: 17,067 Volume weighted average price: .26 EUR____________________________________________ Transaction date: 2020-05-20Venue: FIRST NORTH FINLAND (FNFI)Instrument type: SHAREISIN: FI4000480470Nature of the transaction: ACQUISITION Transaction details(1): Volume: 250,000 Unit price: .0176 EUR Aggregated transactions(1): Volume: 250,000 Volume weighted average price: .0176 EUR Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 [email protected] Erik Penser Bank AB (Certified Adviser) +46 8 463 83 [email protected] About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information please visit www.nexstim.com Attachment Nexstim Company Announcement_Managers Transactions_29032021_1200_EN_FINAL

Continue reading...